Sabrina Cuddy • December 23, 2024
The HCMA theme for January is Setting Your Plan For The Year

You must advocate for yourself to get the best care for your HCM. The first step is to have a plan that includes the tests you need and how often to see your cardiologist. To make planning easier, the HCMA offers Navigation Calls. We encourage everyone with HCM to complete our  Intake and Navigation Call  at least once to help you get on track with your care. This is a free service, although paid members may take advantage of extra calls if needed during the year.

We encourage you to see an HCM expert at an  HCMA Recognized Center of Excellence (COE). We are growing this program to give you more options. For those outside the US, we can often help you find an HCM expert, although we have yet to cover every country.

Is cost limiting your ability to fully take advantage of HCMA services? We offer scholarship memberships. You can apply alone or with your application to the Lori Fund, which grants up to $600 per year to cover the cost of traveling to a COE.

For stable HCM patients, here are some general guidelines for regular  testing

  • Annual Echocardiogram
  • Annual EKG and/or Ambulatory Monitor
  • Annual cardiologist visit
  • Cardiac MRI every 3-5 years

If your symptoms change, you should contact your cardiology team to discuss whether a medication change or other treatment would help you stay stable. Be flexible in your plan to handle changes in your situation. Remember, each patient is different – some can safely go 2-3 years between visits, while others may need to see their team every six months or less.

HCMA Blog

By Erica Friedman June 26, 2025
Investigative journalists Debbie Cenziper, Megan Rose, Brandon Roberts and Irena Hwang from Pro Publica and NPR have concluded a 14-month long investigation into the quality of generic drugs coming into the United States from overseas. Among the many voices that spoke up for American patients was HCMA Founder and CEO, Lisa Salberg who has felt the effects of low-quality drugs personally. Salberg believes that fixing this problem is something we can do, even in this time, when even health care is highly politicized. Read the key takeaways from ProPublica’s 14-month investigation into the FDA’s oversight of foreign drugmakers in Threat in Your Medicine Cabinet: The FDA’s Gamble on America’s Drugs .
A light blue and dark blue paintbrush stroke intersect to make a stylized
By Erica Friedman June 18, 2025
Alnylam press release on the European Commission approval of AMVUTTRA® (vutrisiran) forwild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) as an additional indication
Light & dark blue brush stroke that intersect create an abstract letter 'a' next to the word Alnylam
By Erica Friedman June 17, 2025
AMVUTTRA® (vutrisiran) has been approved by the U.S. Food and Drug Administration (FDA) to treat ATTR-CM in adults.
More Posts